surmount-1 tirzepatide weight loss non-diabetic trial Tirzepatide for the treatment of obesity: Rationale and Weight reduction with different doses

By engaging both GIP and GLP-1 receptors, it enables the investigation of coordinated intracellular signaling events, such as cyclic AMP (cAMP) activation, and the modulation of metabolic pathways

Clinical trials are ongoing to see if tirzepatide can be approved as a weight-loss drug for people without diabetes

Why Thyroid Screening Matters Before Starting Semaglutide Before initiating any GLP-1 therapy, baseline thyroid function testing helps establish your current hormonal state and ensures you're not unknowingly dealing with undiagnosed thyroid disease

Semaglutides are effective at treating type 2 diabetes along with providing weight management

The widespread distribution of GLP-1 receptors means these medications can affect multiple organ systems simultaneously

Evaluation of bias risk The Cochrane revised tool for assessing risk of bias in randomized trials (RoB 2) was utilized to critically assess the papers that were part of our investigation ( Supplementary Appendix S2, S3